Taito Kitano, Daniel A Salmon, Matthew Z Dudley, Ian J Saldanha, Joseph F Levy, J Matthew Austin, David A Thompson, Lilly Engineer
{"title":"个人与社会观点:疫苗接种定量收益-风险评估的意义。","authors":"Taito Kitano, Daniel A Salmon, Matthew Z Dudley, Ian J Saldanha, Joseph F Levy, J Matthew Austin, David A Thompson, Lilly Engineer","doi":"10.1080/14737167.2025.2572319","DOIUrl":null,"url":null,"abstract":"<p><strong>Introductions: </strong>The benefits and risks of each vaccine must be compared prior to their recommendation and again when new evidence emerges.</p><p><strong>Areas covered: </strong>A narrative scoping review was conducted by searching MEDLINE via PubMed on 8 October 2024 and 12 September 2025. The implications of benefit-risk assessments of vaccines are discussed. A quantitative benefit-risk assessment may be conducted from an individual perspective, which only considers direct health effects, or from a societal perspective, which considers both direct and indirect health effects (e.g. a reduction of transmissibility through community immunity). Whether the results of quantitative benefit-risk assessment of vaccination encompass an individual or societal perspective should be made clear as this changes the meaning for stakeholders. A societal perspective is fundamental to evaluating vaccine benefits and risks as a population. However, showing a beneficial impact from a societal perspective may not be sufficient motivation to vaccinate oneself or their children.</p><p><strong>Expert opinion: </strong>Benefit-risk assessments of vaccination from an individual perspective may be helpful for these individuals in their vaccine decision-making. Ideally, timely vaccine benefit-risk assessments from both societal and individual perspectives are conducted in parallel, and the results of both are clearly communicated to the public to aid in vaccine decision-making.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.5000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination.\",\"authors\":\"Taito Kitano, Daniel A Salmon, Matthew Z Dudley, Ian J Saldanha, Joseph F Levy, J Matthew Austin, David A Thompson, Lilly Engineer\",\"doi\":\"10.1080/14737167.2025.2572319\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introductions: </strong>The benefits and risks of each vaccine must be compared prior to their recommendation and again when new evidence emerges.</p><p><strong>Areas covered: </strong>A narrative scoping review was conducted by searching MEDLINE via PubMed on 8 October 2024 and 12 September 2025. The implications of benefit-risk assessments of vaccines are discussed. A quantitative benefit-risk assessment may be conducted from an individual perspective, which only considers direct health effects, or from a societal perspective, which considers both direct and indirect health effects (e.g. a reduction of transmissibility through community immunity). Whether the results of quantitative benefit-risk assessment of vaccination encompass an individual or societal perspective should be made clear as this changes the meaning for stakeholders. A societal perspective is fundamental to evaluating vaccine benefits and risks as a population. However, showing a beneficial impact from a societal perspective may not be sufficient motivation to vaccinate oneself or their children.</p><p><strong>Expert opinion: </strong>Benefit-risk assessments of vaccination from an individual perspective may be helpful for these individuals in their vaccine decision-making. Ideally, timely vaccine benefit-risk assessments from both societal and individual perspectives are conducted in parallel, and the results of both are clearly communicated to the public to aid in vaccine decision-making.</p>\",\"PeriodicalId\":12244,\"journal\":{\"name\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737167.2025.2572319\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2572319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination.
Introductions: The benefits and risks of each vaccine must be compared prior to their recommendation and again when new evidence emerges.
Areas covered: A narrative scoping review was conducted by searching MEDLINE via PubMed on 8 October 2024 and 12 September 2025. The implications of benefit-risk assessments of vaccines are discussed. A quantitative benefit-risk assessment may be conducted from an individual perspective, which only considers direct health effects, or from a societal perspective, which considers both direct and indirect health effects (e.g. a reduction of transmissibility through community immunity). Whether the results of quantitative benefit-risk assessment of vaccination encompass an individual or societal perspective should be made clear as this changes the meaning for stakeholders. A societal perspective is fundamental to evaluating vaccine benefits and risks as a population. However, showing a beneficial impact from a societal perspective may not be sufficient motivation to vaccinate oneself or their children.
Expert opinion: Benefit-risk assessments of vaccination from an individual perspective may be helpful for these individuals in their vaccine decision-making. Ideally, timely vaccine benefit-risk assessments from both societal and individual perspectives are conducted in parallel, and the results of both are clearly communicated to the public to aid in vaccine decision-making.
期刊介绍:
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.